3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
CNS
1
Conditions
Colorectal Neoplasms
5
Rectal Neoplasms
2
Melanoma
2
Colonic Neoplasms
2
Neurofibromatosis 1
1
Lymphatic Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Disease Progression
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Temozolomide
6
Radiosurgery
6
pembrolizumab
4
Magnetic Resonance Spectroscopy
4
Bevacizumab
4
Specimen Handling
3
Nivolumab
3
abemaciclib
2
Watchful Waiting
2
Surveys and Questionnaires
2
Receptors, Interleukin-8B
2
Radiation
2
Mental Status and Dementia Tests
2
Memantine
2
Ipilimumab
2
Biopsy
2
vorasidenib
1
sotorasib
1
sapanisertib
1
ribociclib
1
pertuzumab
1
osimertinib
1
lenvatinib
1
fluciclovine F-18
1
entrectinib
1
encorafenib
1
elacestrant
1
brivaracetam
1
binimetinib
1
Valacyclovir
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
encorafenib
×
30 days
×
Clear all
NCT04074096
2026-06-05
BEPCOME-MB
UNICANCER
Phase 2
Active not recruiting
10 enrolled